Skip to main content

Enliven Therapeutics, Inc.

ELVN
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001672619

In the last 90 days, Enliven Therapeutics, Inc. insiders filed 0 open-market purchases and 8 sales; 214 institutions reported holding it in 13F filings for Q2 2026, worth $4.08B in total; no superinvestor holds it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Enliven Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
8 filings
4 insiders, $11.8M in total
Insiders trading
4
Net value
−$11.8M
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Enliven Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Enliven Therapeutics, Inc.
NameTitleLast reported holdingLast filingFilings, past year
Hohl BenjaminCHIEF FINANCIAL OFFICER38,000Sep 21, 20268
Collins Helen LouiseCHIEF MEDICAL OFFICER25,000Sep 21, 202611
Derynck Mika KDirector0Aug 6, 20262
Kunkel Lori AnneDirector41,884Jul 8, 20264
OrbiMed Advisors LLC10% Owner6,555,102IndirectJun 24, 20262
OrbiMed Capital GP VII LLC10% Owner6,555,102IndirectJun 24, 20262
OrbiMed Genesis GP LLC10% Owner6,555,102IndirectJun 24, 20262
Heyman Richard A.Director22,647IndirectFeb 19, 20264
Garland J. ScottDirector–Feb 17, 20262
Gupta RishiDirector7,663,349IndirectFeb 17, 20261
Bauer JakeDirector87,372Feb 17, 20261
Ballal Rahul D.Director22,341Feb 17, 20261
Lyssikatos Joseph PCHIEF SCIENTIFIC OFFICER18,750Feb 17, 20268
Patel AnishCHIEF OPERATING OFFICER20,000Feb 17, 20265
Fair Richard A.PRESIDENT AND CEO–Dec 12, 20251
Kintz SamuelPRESIDENT AND CEO890,392IndirectNov 19, 20253
Phillips Andrew JohnDirector–Feb 10, 20250
Schwab Andrew J.10% Owner635,341IndirectFeb 16, 20240
Parmar Kush10% Owner635,341IndirectFeb 16, 20240
5AM Opportunities I, L.P.10% Owner635,341IndirectFeb 16, 20240
5AM Ventures VI, L.P.10% Owner635,341IndirectFeb 16, 20240
5AM Opportunities I (GP), LLC10% Owner635,341IndirectFeb 16, 20240
5AM Partners VI, LLC10% Owner635,341IndirectFeb 16, 20240
RA Capital Healthcare Fund LPOther: Former 10% owner2,122,465IndirectFeb 27, 20230
Ra Capital Management, L.P.Other: Former 10% owner2,122,465IndirectFeb 27, 20230
Kolchinsky PeterOther: Former 10% owner2,122,465IndirectFeb 27, 20230
Shah Rajeev M.Other: Former 10% owner2,122,465IndirectFeb 27, 20230
Commodore Capital LP10% Owner1,448,640IndirectFeb 27, 20230
Gray MichaelCFO & COO27,610Feb 22, 20230
Leonard Braden Michael10% Owner1,767,774IndirectJan 5, 20230
Goldfischer CarlDirector–Jun 3, 20220
Mott David MDirector229,224Jun 3, 20220
Bonita David PDirector, 10% Owner4,199,068IndirectJun 3, 20220
Dalton BarbaraDirector–Jun 3, 20220
Conner Edward R.Director–Jun 3, 20220
Chin MarkDirector2,344,072IndirectJun 3, 20220
Williams Laura ADirector–Jun 3, 20220
Kerins Patrick J10% Owner2,611,050Apr 7, 20220
Sandell Scott D10% Owner2,611,050Apr 7, 20220
Baskett Forest10% Owner2,611,050Apr 7, 20220
New Enterprise Associates 14, L.P.10% Owner2,611,050Apr 7, 20220
NEA Partners 14, L.P.10% Owner2,611,050Apr 7, 20220
Nea 14 GP, Ltd10% Owner2,611,050Apr 7, 20220
Sonsini Peter W.10% Owner2,611,050Apr 7, 20220
Florence Anthony A. Jr.10% Owner2,611,050Apr 7, 20220
Attie KennethSVP, CMO34,100Feb 1, 20220
OrbiMed Capital LLCDirector, 10% Owner1,666,666IndirectJul 16, 20210

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Sep 21, 2026 (view filing)5:23 PM ETSep 174 daysHohl BenjaminCHIEF FINANCIAL OFFICERSSale−6.02K$50.35−$303.0K−13.7%38.0K after3 lots10b5-1
Sep 21, 2026 (view filing)5:22 PM ETSep 174 daysCollins Helen LouiseCHIEF MEDICAL OFFICERSSale−5.00K$50.35−$251.8K−16.7%25.0K after3 lots10b5-1
Aug 19, 2026 (view filing)4:17 PM ETAug 172 daysHohl BenjaminCHIEF FINANCIAL OFFICERSSale−6.02K$58.58−$352.6K−13.1%40.0K after2 lots10b5-1
Aug 19, 2026 (view filing)4:16 PM ETAug 172 daysCollins Helen LouiseCHIEF MEDICAL OFFICERSSale−5.00K$58.59−$292.9K−16.7%25.0K after2 lots10b5-1
Aug 6, 2026 (view filing)8:18 PM ETAug 42 daysDerynck Mika KDirectorSSale−158.8K$60.21−$9.56M−100.0%0 after10b5-1
Jul 21, 2026 (view filing)5:24 PM ETJul 174 daysHohl BenjaminCHIEF FINANCIAL OFFICERSSale−6.02K$52.64−$316.8K−11.6%46.1K after5 lots10b5-1
Jul 21, 2026 (view filing)5:23 PM ETJul 174 daysCollins Helen LouiseCHIEF MEDICAL OFFICERSSale−5.00K$52.67−$263.4K−16.7%25.0K after5 lots10b5-1
Jul 8, 2026 (view filing)5:15 PM ETJul 62 daysKunkel Lori AnneDirectorSSale−10.0K$50.49−$504.9K−19.3%41.9K after2 lots10b5-1
Jun 24, 2026 (view filing)7:19 PM ETJun 222 daysOrbiMed Advisors LLC and 2 others10% OwnerSSale−860.1K$45.36−$39.0M−11.6%6.56M after4 lots
Jun 22, 2026 (view filing)Jun 175 daysHohl BenjaminCHIEF FINANCIAL OFFICERSSale−6.02K$43.80−$263.6K−10.6%51.0K after3 lots10b5-1
Jun 22, 2026 (view filing)Jun 175 daysCollins Helen LouiseCHIEF MEDICAL OFFICERSSale−5.00K$43.80−$219.0K−16.7%25.0K after3 lots10b5-1
Jun 17, 2026 (view filing)7:45 PM ETJun 152 daysOrbiMed Advisors LLC and 2 others10% OwnerSSale−281.4K$45.02−$12.7M−3.7%7.39M after2 lots
Jun 9, 2026 (view filing)Jun 54 daysKunkel Lori AnneDirectorSSale−10.0K$34.54−$345.4K−16.2%51.9K after3 lots10b5-1
May 20, 2026 (view filing)May 182 daysCollins Helen LouiseCHIEF MEDICAL OFFICERSSale−5.00K$39.79−$199.0K−16.7%25.0K after3 lots10b5-1
Apr 21, 2026 (view filing)Apr 174 daysCollins Helen LouiseCHIEF MEDICAL OFFICERSSale−5.00K$47.67−$238.4K−16.7%25.0K after3 lots10b5-1
Mar 27, 2026 (view filing)Mar 252 daysCollins Helen LouiseCHIEF MEDICAL OFFICERSSale−40.0K$35.10−$1.40M−61.5%25.0K after10b5-1
Mar 19, 2026 (view filing)Mar 172 daysCollins Helen LouiseCHIEF MEDICAL OFFICERSSale−5.00K$27.76−$138.8K−16.7%25.0K after10b5-1
Mar 11, 2026 (view filing)Mar 9-102 daysCollins Helen LouiseCHIEF MEDICAL OFFICERSSale−40.0K$30.06−$1.20M−61.5%25.0K after2 lots10b5-1
Mar 10, 2026 (view filing)Mar 64 daysHohl BenjaminCHIEF FINANCIAL OFFICERSSale−10.0K$29.58−$295.8K−16.4%51.0K after
Feb 19, 2026 (view filing)Feb 172 daysCollins Helen LouiseCHIEF MEDICAL OFFICERSSale−45.0K$26.17−$1.18M−64.3%25.0K after10b5-1
Feb 19, 2026 (view filing)Feb 172 daysHeyman Richard A.DirectorSSale−1.23K$26.18−$32.2K−5.2%22.6K after10b5-1
Feb 10, 2026 (view filing)Feb 64 daysLyssikatos Joseph PCHIEF SCIENTIFIC OFFICERSSale−5.00K$29.04−$145.2K−0.7%740.2K after10b5-1
Jan 22, 2026 (view filing)Jan 202 daysLyssikatos Joseph PCHIEF SCIENTIFIC OFFICERSSale−20.0K$26.75−$535.1K−2.6%745.2K after2 lots10b5-1
Jan 22, 2026 (view filing)Jan 202 daysHeyman Richard A.DirectorSSale−1.23K$26.75−$32.9K−4.9%23.9K after2 lots10b5-1
Jan 13, 2026 (view filing)Jan 94 daysPatel AnishCHIEF OPERATING OFFICERSSale−48.3K$27.98−$1.35M−18.3%215.0K after2 lots10b5-1
Jan 12, 2026 (view filing)Jan 8-94 daysLyssikatos Joseph PCHIEF SCIENTIFIC OFFICERSSale−132.5K$26.23−$3.48M−14.8%765.2K after4 lots10b5-1
Jan 12, 2026 (view filing)Jan 8-94 daysHeyman Richard A.DirectorSSale−13.9K$25.02−$348.3K−35.7%25.1K after3 lots10b5-1
Dec 23, 2025 (view filing)Dec 194 daysLyssikatos Joseph PCHIEF SCIENTIFIC OFFICERSSale−5.00K$16.84−$84.2K−0.6%897.7K after10b5-1
Dec 10, 2025 (view filing)Dec 82 daysPatel AnishCHIEF OPERATING OFFICERSSale−6.66K$21.02−$140.1K−2.5%263.3K after2 lots10b5-1
Nov 21, 2025 (view filing)Nov 192 daysLyssikatos Joseph PCHIEF SCIENTIFIC OFFICERSSale−12.5K$22.33−$279.1K−1.4%902.7K after2 lots10b5-1
Nov 19, 2025 (view filing)Nov 172 daysKintz SamuelPRESIDENT AND CEOSSale−12.5K$21.82−$272.8K−1.4%890.4K after10b5-1
Nov 12, 2025 (view filing)Nov 75 daysPatel AnishCHIEF OPERATING OFFICERSSale−6.67K$17.40−$116.0K−2.4%270.0K after2 lots10b5-1
Oct 22, 2025 (view filing)Oct 202 daysLyssikatos Joseph PCHIEF SCIENTIFIC OFFICERSSale−12.5K$22.08−$276.0K−1.3%915.2K after10b5-1
Oct 21, 2025 (view filing)Oct 174 daysKintz SamuelPRESIDENT AND CEOSSale−12.5K$21.33−$266.6K−1.4%902.9K after10b5-1
Oct 9, 2025 (view filing)Oct 72 daysPatel AnishCHIEF OPERATING OFFICERSSale−6.67K$20.10−$134.0K−2.4%276.6K after10b5-1
Oct 1, 2025 (view filing)Sep 292 daysHohl BenjaminCHIEF FINANCIAL OFFICERSSale−3.25K$20.40−$66.3K−12.4%23.0K after10b5-1
Sep 30, 2025 (view filing)Sep 264 daysKintz SamuelPRESIDENT AND CEOSSale−3.70K$20.06−$74.2K−0.4%915.4K after10b5-1
Sep 30, 2025 (view filing)Sep 264 daysLyssikatos Joseph PCHIEF SCIENTIFIC OFFICERSSale−4.00K$20.25−$81.0K−0.4%927.7K after10b5-1
Sep 25, 2025 (view filing)Sep 232 daysKintz SamuelPRESIDENT AND CEOSSale−2.80K$20.03−$56.1K−0.3%919.1K after10b5-1
Sep 25, 2025 (view filing)Sep 232 daysLyssikatos Joseph PCHIEF SCIENTIFIC OFFICERSSale−1.50K$20.03−$30.0K−0.2%931.7K after10b5-1
Sep 23, 2025 (view filing)Sep 194 daysLyssikatos Joseph PCHIEF SCIENTIFIC OFFICERSSale−7.00K$19.39−$135.7K−0.7%933.2K after2 lots10b5-1
Sep 19, 2025 (view filing)Sep 17-192 daysKintz SamuelPRESIDENT AND CEOSSale−6.00K$19.28−$115.7K−0.6%921.9K after2 lots10b5-1
Sep 10, 2025 (view filing)Sep 82 daysPatel AnishCHIEF OPERATING OFFICERSSale−6.67K$20.24−$134.9K−2.3%283.3K after10b5-1
Aug 29, 2025 (view filing)Aug 272 daysHohl BenjaminCHIEF FINANCIAL OFFICERSSale−3.25K$20.63−$67.0K−12.4%23.0K after10b5-1
Aug 21, 2025 (view filing)Aug 201 dayKintz SamuelPRESIDENT AND CEOSSale−1.52K$20.00−$30.3K−0.2%927.9K afterAmended10b5-1
Aug 21, 2025 (view filing)Aug 19-212 daysLyssikatos Joseph PCHIEF SCIENTIFIC OFFICERSSale−12.5K$19.85−$248.2K−1.3%940.2K after2 lots10b5-1
Aug 11, 2025 (view filing)Aug 74 daysPatel AnishCHIEF OPERATING OFFICERSSale−6.67K$18.24−$121.6K−2.2%290.0K after2 lots10b5-1
Jul 30, 2025 (view filing)Jul 282 daysHohl BenjaminCHIEF FINANCIAL OFFICERSSale−3.25K$20.47−$66.5K−12.4%23.0K after2 lots10b5-1
Jul 23, 2025 (view filing)Jul 212 daysLyssikatos Joseph PCHIEF SCIENTIFIC OFFICERSSale−12.5K$22.29−$278.6K−1.3%952.7K after2 lots10b5-1
Jul 21, 2025 (view filing)Jul 174 daysKintz SamuelPRESIDENT AND CEOSSale−12.5K$22.52−$281.5K−1.3%940.4K after3 lots10b5-1